Dr Reddy's Labs launches Amphetamine Sulfate Tablets USP in US Market

Hyderabad and Princeton: Dr Reddy's Laboratories Ltd. has announced the launch of Amphetamine Sulfate Tablets USP, a therapeutic equivalent generic version of Evekeo® (amphetamine sulfate) Tablets approved by the U.S. Food and Drug Administration (USFDA). Amphetamine Sulfate Tablets, USP is a Schedule II drug.

The Evekeo® brand and generic had U.S. sales of approximately $38 million MAT for the most recent twelve months ending in January 2020 according to IQVIA Health*.

Dr. Reddy's Amphetamine Sulfate Tablets USP are available in 5 mg and 10 mg dose in bottle count sizes of 100.

Dr. Reddy's Laboratories Ltd. is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.

Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics, and Proprietary Products- Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, and differentiated formulations.

Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. Dr. Reddy's operates in markets across the globe. Its major markets include – USA, India, Russia & CIS countries, and Europe.

Read also: Dr Reddy's Labs Receives EIR For Nalgonda-Based API Plant